• Ultragenyx signed a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 203 million.
• The voucher was awarded on FDA clearance of FAYUVI (UX111) for mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome Type A.
• Closing remains subject to customary conditions, including expiration of the Hart-Scott-Rodino waiting period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140830PRIMZONEFULLFEED9845228) on October 14, 2026, and is solely responsible for the information contained therein.